



This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Other				
Hearing loss	Usher syndrome 1C (USH1C)	Mouse studies suggest using antisense oligonucleotides (ASOs) that correct splicing of mutant USH1C transcripts could help prevent Usher syndrome–associated hearing loss. In a neonatal mouse model of Usher syndrome, a single intraperitoneal injection of a splice-correcting ASO prevented development of auditory and vestibular defects, whereas injection of a control ASO did not. Next steps include optimizing the lead ASO and determining the best dosing regimen in collaboration with Isis Pharmaceuticals Inc.	Patents pending covering ASOs targeted to the mutant USH1C; licensing status undisclosed	Lentz, J.J. et al. Nat. Med.; published online Feb. 4, 2013; doi:10.1038/nm.3106 Contact: Michelle L. Hastings, Rosalind Franklin University of Medicine and Science, Chicago, Ill. e-mail: michelle.hastings@rosalindfranklin.edu
		SciBX 6(7); doi:10.1038/scibx.2013.171 Published online Feb. 21, 2013		